Repeat Clot-Busting Drug Within 90 Days May Be Safer Than Stroke Rules Assume

For nearly three decades, one of the most consequential rules in emergency stroke medicine has rested less on hard data than on expert caution: if a patient has suffered an ischemic stroke within the past three months, intravenous thrombolysis — the powerful clot-dissolving therapy that can rescue threatened brain tissue — is generally withheld. The concern is intuitive. Thrombolytic drugs such as alteplase and tenecteplase work by activating plasmin, the body’s principal fibrin-degrading enzyme, and physicians have long feared that a second dose delivered before a recent infarct has fully healed could rupture fragile vessels and trigger a catastrophic bleed inside the skull. Now, a systematic review and individual-patient data meta-analysis published in the Journal of Neurology by a team of Italian stroke specialists is challenging that assumption with the most granular evidence assembled to date.

The study, led by Irene Scala of the Cerebrovascular Unit at Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan and conducted on behalf of the Italian Stroke Association (ISA)-Young, set out to answer a deceptively simple question: what actually happens when patients receive repeated intravenous thrombolysis (RIVT) for a recurrent acute ischemic stroke within 90 days of a previous thrombolysis-treated event? The researchers systematically screened the literature and identified 28 reports describing 63 patients who underwent the procedure, with individual patient-level data available for 44 of those cases. That patient-level granularity matters enormously in a field dominated by small case series, because it allowed the team to analyze outcomes at the level of individual strokes rather than pooled study averages, reducing the aggregation bias that has plagued earlier reviews.

The headline finding is striking. Among patients who received a second course of intravenous thrombolysis within the three-month window, 66.7 percent achieved a favorable functional outcome — a proportion that compares respectably with outcomes reported for first-time thrombolysis in routine clinical registries. The median interval between the two treatments was just 7.5 days, meaning most of these patients were re-dosed while their initial infarcts were still biologically fresh, precisely the scenario in which the feared hemorrhagic risk was thought to be highest. Yet across the entire dataset, not a single case of symptomatic intracranial hemorrhage (sICH) — the dreaded complication that the three-month exclusion criterion was designed to prevent — was recorded after repeated thrombolysis.

Formal meta-analysis reinforced the picture. The pooled odds ratio for better functional outcomes after repeated thrombolysis was 1.52, with a 95 percent confidence interval of 0.97 to 2.39 and zero heterogeneity across studies (I² = 0%). The confidence interval crosses one, so the trend toward benefit does not reach statistical significance, but the direction is consistent and the absence of heterogeneity suggests the underlying case reports tell a remarkably uniform story. Equally important, the analysis found no significant increase in functional deterioration between stroke episodes, with a pooled odds ratio of 1.28 (95% CI 0.75–2.19; I² = 0%). In other words, patients did not systematically worsen after their second stroke, and there was no signal that the repeat treatment itself drove neurological decline.

Perhaps the most clinically useful aspect of the analysis is what it ruled out. The researchers tested whether outcomes were influenced by the interval between treatments, patient age, sex, stroke etiology, vascular territory, or the time from symptom onset to treatment — and found that none of these factors significantly shaped results. This null finding directly undermines the logic of a fixed temporal cutoff. If the safety of a second dose does not measurably depend on how many days have elapsed since the first stroke, then a rigid three-month clock may be the wrong instrument for judging risk. Instead, the data suggest clinicians should weigh the individual biology of each recurrence rather than the calendar.

The safety signal was not entirely clean, and the authors are careful to report it. Asymptomatic intracranial or systemic hemorrhages occurred in 15.9 percent of patients — bleeding visible on imaging or detected clinically but not causing neurological worsening. Fatal events occurred in 5 percent of cases, but crucially, these deaths were unrelated to neurological complications. Both hemorrhagic and fatal events clustered predominantly in patients with cardioembolic strokes and more severe initial presentations, hinting that the underlying mechanism of recurrence and stroke severity, rather than the repeat thrombolysis itself, may drive adverse outcomes. This pattern aligns with mechanistic reasoning: cardioembolic strokes, often arising from atrial fibrillation or cardiac thrombi, tend to be larger and more lethal, and patients with severe deficits have more tissue at risk regardless of treatment.

To understand why the three-month rule exists at all, one has to look back to the founding trials of stroke thrombolysis. The 1995 NINDS trial of tissue plasminogen activator, which established alteplase as standard care, excluded patients with recent stroke, and subsequent guidelines from the European Stroke Organisation and the American Heart Association/American Stroke Association carried the exclusion forward as a relative contraindication grounded largely in expert consensus rather than dedicated trials of repeat dosing. The biological rationale — that freshly infarcted brain and reperfused vessels are more prone to bleeding — has never been disproven, but it has also never been rigorously quantified in the recurrent-stroke setting. Meanwhile, the clinical dilemma is real and growing: patients with active sources of embolism, unstable atherosclerotic plaques, carotid webs, free-floating thrombi, or basilar artery occlusions can suffer devastating recurrent strokes days or weeks after a first event, and withholding thrombolysis from them may condemn them to disability or death.

The new analysis, registered prospectively in PROSPERO (CRD420251276423) and conducted according to PRISMA 2020 reporting standards, synthesizes a literature that spans two decades of case reports and small series — from early accounts of imaging-guided repeat dosing in 2005 to multicenter case studies of ultra-early re-treatment published in 2023. The authors used the Heidelberg bleeding classification to standardize hemorrhage assessment and performed the meta-analysis with established statistical tooling. By extracting individual patient data wherever possible, they converted a scattered, anecdotal literature into something approaching coherent evidence — a methodological upgrade that previous systematic reviews of the same question, which relied on aggregated study-level data, could not achieve.

The caveats are substantial and the authors acknowledge them plainly. Repeated thrombolysis within 90 days is a rare event, and its efficacy remains understudied; the 63 patients analyzed come from published reports that are inherently subject to publication bias, since dramatic successes and instructive failures are more likely to reach print than unremarkable outcomes. There are no randomized trials, no matched controls who were denied repeat thrombolysis, and no way to fully separate the effect of treatment from the effect of careful patient selection — the very clinicians who chose to re-treat these patients presumably judged them to be favorable candidates. The favorable outcomes observed may partly reflect that selection rather than the safety of the drug itself. Five percent mortality, even if neurologically unrelated, is not negligible in an already fragile population.

Still, the conclusion the authors draw is measured and potentially practice-changing: repeated intravenous thrombolysis within 90 days may be a reasonable reperfusion strategy in carefully selected patients with recurrent acute ischemic stroke, and the interval from the previous stroke should not be treated as an isolated exclusion criterion. In an era when mechanical thrombectomy is increasingly available but not always feasible — particularly for distal vessel occlusions or in centers without endovascular capability — the finding suggests that the pharmacological route should not be automatically closed by the calendar. The evidence is observational and thin, but for a rule that has governed stroke units worldwide on the strength of consensus alone, the burden of proof may now have shifted. Larger, prospective registries of recurrent stroke treatment will be needed to confirm whether the zero-sICH finding holds at scale, but for clinicians facing a deteriorating patient with a fresh recurrence, this analysis offers something they have rarely had: data suggesting that saying yes to a second dose may not be the reckless act the guidelines have long implied.

Subject of Research: Safety and efficacy of repeated intravenous thrombolysis within three months for recurrent acute ischemic stroke

Article Title: Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis

Article References: Scala, I., Ciacciarelli, A., Cancelloni, V., Digiovanni, A., Galotto, D., Gardin, A., Giammello, F., & the Italian Stroke Association (ISA)-Young (2026). Safety and efficacy of repeated intravenous thrombolysis within 3 months for acute ischemic stroke: a systematic review and individual-patient data meta-analysis. Journal of Neurology, 273(10), Article 607. https://doi.org/10.1007/s00415-026-14144-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14144-x

Keywords: stroke, intravenous thrombolysis, recurrent stroke, alteplase, symptomatic intracranial hemorrhage, meta-analysis, systematic review, cerebrovascular disease, reperfusion therapy, stroke guidelines, neurology, thrombolytic drugs